Femasys announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 16/402,193 further strengthening Femasys’ intellectual property position and coverage for the Company’s therapeutic product candidate, FemBloc permanent birth control. Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039 at the earliest. Femasys intends to continue to prosecute additional patent applications to further enhance its existing patent portfolio protecting FemBloc along with FemaSeed localized directional insemination for infertility treatment, representing the two lead product candidates of the Company, in addition to the Company’s existing available diagnostic products, FemVue, FemCath, and FemCerv.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
- Femasys announces FDA approvalof IDE for FemBloc clinical trial
- Femasys files to sell 3.39M shares of common stock for holders
- Femasys appoints Keith Kendall, Alistair Milnes to board of directors
- Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada